Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Roman Zilbershtein"'
Autor:
Charles Piwko, Roman Zilbershtein, R. Jensen, M Hemels, Hanna Pudas, Thomas R. Einarson, Christel N Bø, Colin Vicente
Publikováno v:
Nordic Journal of Psychiatry. 68:416-427
To determine the cost-effectiveness of long-acting injectable (LAI) antipsychotics for chronic schizophrenia in Sweden.A 1-year decision tree was developed for Sweden using published data and expert opinion. Five treatment strategies lasting 1 year w
Publikováno v:
Journal of Medical Economics. 16:1089-1095
The Czech Republic is faced with making choices between pharmaceutical products, including depot injectable antipsychotics. A pharmacoeconomic analysis was conducted to determine the cost-effectiveness of atypical depots.An existing 1-year decision-a
Autor:
Hanna Pudas, Thomas R. Einarson, Roman Zilbershtein, Colin Vicente, Michiel E. H. Hemels, Christel N. Bø, Charles Piwko
Publikováno v:
Acta Neuropsychiatrica. 25:85-94
ObjectivePaliperidone palmitate long‐acting injection (PP‐LAI) has recently been approved for treatment of chronic schizophrenia. Its cost‐effectiveness has not been established. The objective was to compare direct costs and outcomes between PP
Autor:
Thomas R. Einarson, Colin Vicente, R. Jensen, Charles Piwko, Roman Zilbershtein, M Hemels, Hanna Pudas
Publikováno v:
Journal of medical economics. 16(9)
In Finland, regional rates of schizophrenia exceed those in most countries, impacting the healthcare burden. This study determined the cost-effectiveness of long-acting antipsychotic (LAI) drugs paliperidone palmitate (PP-LAI), olanzapine pamoate (OL
Autor:
Dionyssios Potamitis-Komis, Colin Vicente, Konstantina Paparouni, Thomas R. Einarson, Maria Geitona, Panagiotis Kakkavas, Periklis Paterakis, Dimitrios Ploumpidis, Alexandros Chaidemenos, Theodoros Mougiakos, Charles Piwko, Vasiliki Karpouza, R. Jensen, Roman Zilbershtein, M Hemels
Publikováno v:
Annals of General Psychiatry
Annals of General Psychiatry, Vol 11, Iss 1, p 18 (2012)
Annals of General Psychiatry, Vol 11, Iss 1, p 18 (2012)
Background Patients having chronic schizophrenia with frequent relapses and hospitalizations represent a great challenge, both clinically and financially. Risperidone long-acting injection (RIS-LAI) has been the main LAI atypical antipsychotic treatm
Autor:
R. Jensen, Miroslav Herceg, Thomas R. Einarson, Vlado Jukić, M Hemels, Roman Zilbershtein, Ante Silić, Tatjana Tomljanovic, Igor Filipčić, Miro Jakovljević
Publikováno v:
Value in Health Regional Issues. (2):181-188
Objectives: As a nation with a developing economy, Croatia is faced with making choices between pharmaceutical products, including depot injectable antipsychotics. We conducted a pharmacoeconomic analysis to determine the cost-effectiveness of atypic
Autor:
Einarson, Thomas R.1 (AUTHOR) t.einarson@rogers.com, Vicente, Colin2 (AUTHOR), Zilbershtein, Roman3 (AUTHOR), Piwko, Charles4 (AUTHOR), Bø, Christel N.5 (AUTHOR), Pudas, Hanna6 (AUTHOR), Jensen, Rasmus7 (AUTHOR), Hemels, Michiel E.H.8 (AUTHOR)
Publikováno v:
Nordic Journal of Psychiatry. Aug2014, Vol. 68 Issue 6, p416-427. 12p.
Autor:
Einarson, Thomas R., Vicente, Colin, Zilbershtein, Roman, Piwko, Charles, Bø, Christel N., Pudas, Hanna, Hemels, Michiel E. H.
Publikováno v:
Acta Neuropsychiatrica; Apr2013, Vol. 25 Issue 2, p85-94, 10p